BEI
VRTX icon

Benjamin Edwards Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Benjamin Edwards Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.48M Sell
11,025
-92
-0.8% -$40.8K 0.05% 331
2026
Q1 		$4.97M Buy
11,117
+24
+0.2% +$11.2K 0.05% 333
2025
Q4 		$5.03M Buy
11,093
+597
+6% +$257K 0.06% 304
2025
Q3 		$4.11M Buy
10,496
+862
+9% +$360K 0.05% 335
2025
Q2 		$4.29M Buy
9,634
+1,428
+17% +$658K 0.05% 304
2025
Q1 		$3.98M Buy
8,206
+827
+11% +$385K 0.06% 295
2024
Q4 		$2.97M Buy
7,379
+711
+11% +$330K 0.04% 356
2024
Q3 		$3.1M Buy
6,668
+6,535
+4,914% +$3.14M 0.05% 345
2024
Q2 		$62K Buy
133
+19
+17% +$8.25K 0.01% 476
2024
Q1 		$48K Buy
+114
New +$48.2K 0.01% 487
2022
Q2 		– Sell
-17
Closed -$4K – 748
2022
Q1 		$4K Buy
17
+9
+113% +$2.14K ﹤0.01% 664
2021
Q4 		$2K Buy
8
+3
+60% +$583 ﹤0.01% 684
2021
Q3 		$1K Buy
+5
New +$976 ﹤0.01% 532

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Benjamin Edwards Inc's VRTX Position: Q2 2026 in Review

Benjamin Edwards Inc reduced its Vertex Pharmaceuticals (VRTX) stake by 0.83% in Q2 2026, selling an estimated $40.8K and leaving 11,025 shares worth $5.48M. The position accounts for 0.05% of the portfolio, ranked #331.

Benjamin Edwards Inc first reported a position in VRTX in Q3 2021 and has held it in 13 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Benjamin Edwards Inc held 11,025 shares of Vertex Pharmaceuticals worth $5.48M as of Q2 2026.
  • Benjamin Edwards Inc sold 92 Vertex Pharmaceuticals shares in Q2 2026, an estimated $40.8K.
  • Vertex Pharmaceuticals made up 0.05% of Benjamin Edwards Inc's portfolio in Q2 2026, its #331 holding.
  • Benjamin Edwards Inc first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 13 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Benjamin Edwards Inc's 13F filing for Q2 2026, filed 24 Jul 2026.